Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation

Mitsuru Futakuchi, Kalyan C. Nannuru, Michelle L. Varney, Anguraj Sadanandam, Kimihisa Nakao, Kiyofumi Asai, Tomoyuki Shirai, Shin Ya Sato, Rakesh K Singh

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Understanding the cellular and molecular changes in the bone microenvironment is important for developing novel therapeutics to control breast cancer bone metastasis. Although the underlying mechanism(s) of bone metastasis has been the focus of intense investigation, relatively little is known about complex molecular interactions between malignant cells and bone stroma. Using a murine syngeneic model that mimics osteolytic changes associated with human breast cancer, we examined the role of tumor-bone interaction in tumor-induced osteolysis and malignant growth in the bone microenvironment. We identified transforming growth factor-β receptor 1 (TGF-βRI) as a commonly upregulated gene at the tumor-bone (TB) interface. Moreover, TGF-βRI expression and activation, analyzed by nuclear localization of phospho-Smad2, was higher in tumor cells and osteoclasts at the TB interface as compared to the tumor-alone area. Furthermore, attenuation of TGF-β activity by neutralizing antibody to TGF-β or TGF-βRI kinase inhibitor reduced mammary tumor-induced osteolysis, TGF-βRI expression and its activation. In addition, we demonstrate a potential role of TGF-β as an important modifier of receptor activator of NF-κB ligand (RANKL)-dependent osteoclast activation and osteolysis. Together, these studies demonstrate that inhibition of TGF-βRI signaling at the TB interface will be a therapeutic target in the treatment of breast cancer-induced osteolysis.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalCancer Science
Volume100
Issue number1
DOIs
StatePublished - Jan 13 2009

Fingerprint

Transforming Growth Factors
Osteoclasts
Osteolysis
Breast Neoplasms
Bone and Bones
Growth
Neoplasms
Neoplasm Metastasis
Bone Neoplasms
Growth Factor Receptors
Bone Development
Neutralizing Antibodies
Phosphotransferases
Ligands
Therapeutics
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. / Futakuchi, Mitsuru; Nannuru, Kalyan C.; Varney, Michelle L.; Sadanandam, Anguraj; Nakao, Kimihisa; Asai, Kiyofumi; Shirai, Tomoyuki; Sato, Shin Ya; Singh, Rakesh K.

In: Cancer Science, Vol. 100, No. 1, 13.01.2009, p. 71-81.

Research output: Contribution to journalArticle

Futakuchi, M, Nannuru, KC, Varney, ML, Sadanandam, A, Nakao, K, Asai, K, Shirai, T, Sato, SY & Singh, RK 2009, 'Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation', Cancer Science, vol. 100, no. 1, pp. 71-81. https://doi.org/10.1111/j.1349-7006.2008.01012.x
Futakuchi, Mitsuru ; Nannuru, Kalyan C. ; Varney, Michelle L. ; Sadanandam, Anguraj ; Nakao, Kimihisa ; Asai, Kiyofumi ; Shirai, Tomoyuki ; Sato, Shin Ya ; Singh, Rakesh K. / Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. In: Cancer Science. 2009 ; Vol. 100, No. 1. pp. 71-81.
@article{67b482ea02d24880a45191ba9778f480,
title = "Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation",
abstract = "Understanding the cellular and molecular changes in the bone microenvironment is important for developing novel therapeutics to control breast cancer bone metastasis. Although the underlying mechanism(s) of bone metastasis has been the focus of intense investigation, relatively little is known about complex molecular interactions between malignant cells and bone stroma. Using a murine syngeneic model that mimics osteolytic changes associated with human breast cancer, we examined the role of tumor-bone interaction in tumor-induced osteolysis and malignant growth in the bone microenvironment. We identified transforming growth factor-β receptor 1 (TGF-βRI) as a commonly upregulated gene at the tumor-bone (TB) interface. Moreover, TGF-βRI expression and activation, analyzed by nuclear localization of phospho-Smad2, was higher in tumor cells and osteoclasts at the TB interface as compared to the tumor-alone area. Furthermore, attenuation of TGF-β activity by neutralizing antibody to TGF-β or TGF-βRI kinase inhibitor reduced mammary tumor-induced osteolysis, TGF-βRI expression and its activation. In addition, we demonstrate a potential role of TGF-β as an important modifier of receptor activator of NF-κB ligand (RANKL)-dependent osteoclast activation and osteolysis. Together, these studies demonstrate that inhibition of TGF-βRI signaling at the TB interface will be a therapeutic target in the treatment of breast cancer-induced osteolysis.",
author = "Mitsuru Futakuchi and Nannuru, {Kalyan C.} and Varney, {Michelle L.} and Anguraj Sadanandam and Kimihisa Nakao and Kiyofumi Asai and Tomoyuki Shirai and Sato, {Shin Ya} and Singh, {Rakesh K}",
year = "2009",
month = "1",
day = "13",
doi = "10.1111/j.1349-7006.2008.01012.x",
language = "English (US)",
volume = "100",
pages = "71--81",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation

AU - Futakuchi, Mitsuru

AU - Nannuru, Kalyan C.

AU - Varney, Michelle L.

AU - Sadanandam, Anguraj

AU - Nakao, Kimihisa

AU - Asai, Kiyofumi

AU - Shirai, Tomoyuki

AU - Sato, Shin Ya

AU - Singh, Rakesh K

PY - 2009/1/13

Y1 - 2009/1/13

N2 - Understanding the cellular and molecular changes in the bone microenvironment is important for developing novel therapeutics to control breast cancer bone metastasis. Although the underlying mechanism(s) of bone metastasis has been the focus of intense investigation, relatively little is known about complex molecular interactions between malignant cells and bone stroma. Using a murine syngeneic model that mimics osteolytic changes associated with human breast cancer, we examined the role of tumor-bone interaction in tumor-induced osteolysis and malignant growth in the bone microenvironment. We identified transforming growth factor-β receptor 1 (TGF-βRI) as a commonly upregulated gene at the tumor-bone (TB) interface. Moreover, TGF-βRI expression and activation, analyzed by nuclear localization of phospho-Smad2, was higher in tumor cells and osteoclasts at the TB interface as compared to the tumor-alone area. Furthermore, attenuation of TGF-β activity by neutralizing antibody to TGF-β or TGF-βRI kinase inhibitor reduced mammary tumor-induced osteolysis, TGF-βRI expression and its activation. In addition, we demonstrate a potential role of TGF-β as an important modifier of receptor activator of NF-κB ligand (RANKL)-dependent osteoclast activation and osteolysis. Together, these studies demonstrate that inhibition of TGF-βRI signaling at the TB interface will be a therapeutic target in the treatment of breast cancer-induced osteolysis.

AB - Understanding the cellular and molecular changes in the bone microenvironment is important for developing novel therapeutics to control breast cancer bone metastasis. Although the underlying mechanism(s) of bone metastasis has been the focus of intense investigation, relatively little is known about complex molecular interactions between malignant cells and bone stroma. Using a murine syngeneic model that mimics osteolytic changes associated with human breast cancer, we examined the role of tumor-bone interaction in tumor-induced osteolysis and malignant growth in the bone microenvironment. We identified transforming growth factor-β receptor 1 (TGF-βRI) as a commonly upregulated gene at the tumor-bone (TB) interface. Moreover, TGF-βRI expression and activation, analyzed by nuclear localization of phospho-Smad2, was higher in tumor cells and osteoclasts at the TB interface as compared to the tumor-alone area. Furthermore, attenuation of TGF-β activity by neutralizing antibody to TGF-β or TGF-βRI kinase inhibitor reduced mammary tumor-induced osteolysis, TGF-βRI expression and its activation. In addition, we demonstrate a potential role of TGF-β as an important modifier of receptor activator of NF-κB ligand (RANKL)-dependent osteoclast activation and osteolysis. Together, these studies demonstrate that inhibition of TGF-βRI signaling at the TB interface will be a therapeutic target in the treatment of breast cancer-induced osteolysis.

UR - http://www.scopus.com/inward/record.url?scp=58149307506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149307506&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2008.01012.x

DO - 10.1111/j.1349-7006.2008.01012.x

M3 - Article

VL - 100

SP - 71

EP - 81

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -